Hemodynamic deterioration of surgically implanted bioprosthetic aortic valves. J Am Coll Cardiol. 2018;72:241 51. 13. Dvir D, Bourguignon T, Otto CM, et al. Standardized definition of struc- tural valve degeneration for surgical and transcatheter bioprosthetic aortic valves. Circulation. 2018;137:388 99. 14. Douglas PS, Leon MB, Mack MJ, et al. Longitudinal hemodynamics of transcatheter and surgical aortic valves in the PARTNER trial. JAMA Car- diol. 2017;2:1197 206. 15. Mack MJ, Leon MB, Smith CR, et al. 5-year outcomes of transcatheter aor- tic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385:2477 84. 16. Kapadia SR, Leon MB, Makkar RR, et al. 5-Year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385:2485 91. 17. Fernandez-Santos S, Th ron A, Pibarot P, et al. Valve hemodynamic per- formance and myocardial strain after implantation of a third-generation, balloon-expandable, transcatheter aortic valve. Cardiol J. 2019 May 20. Online ahead of print. doi:10.5603/CJ.a2019.0049 18. Manoharan G, Van Mieghem NM, Windecker S, et al. 1-Year outcomes with the Evolut R self-expanding transcatheter aortic valve: from the inter- national FORWARD study. JACC Cardiovasc Interv. 2018;11:2326 34. CLINICAL STATEMENTS AND GUIDELINES 19. Gleason TG, Reardon MJ, Popma JJ, et al. 5-Year outcomes of self-ex- panding transcatheter versus surgical aortic valve replacement in high-risk patients. J Am Coll Cardiol. 2018;72:2687 96. 20. Blackman DJ, Saraf S, MacCarthy PA, et al. Long-term durability of trans- catheter aortic valve prostheses. J Am Coll Cardiol. 2019;73:537 45. 21. S ndergaard L, Ihlemann N, Capodanno D, et al. Durability of transcath- eter and surgical bioprosthetic aortic valves in patients at lower surgical risk. J Am Coll Cardiol. 2019;73:546 53. 11.2.1. 